

ASX Announcement

23 October 2026

Addendum to Notice of Annual General Meeting (AGM)

Genetic Signatures Limited (ASX:GSS) advises that the following documents relating to the Addendum to the Notice of the Annual General Meeting of the Company, to be held at 9:00am (Sydney time) on Monday, 16 November 2026, are attached:

- Addendum to the Notice of Annual General Meeting
- Updated Proxy Form
- Notice and Access Letter

This announcement has been authorised for release by the Board of Directors of Genetic Signatures Limited.

– END –

For further information, see our website (www.geneticsignatures.com) or contact us:

Sonya Tissera
Company Secretary
Genetic Signatures Limited

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.



GENETIC SIGNATURES LIMITED

ACN 095 913 205

ADDENDUM TO NOTICE OF ANNUAL GENERAL MEETING

Genetic Signatures Limited (ASX: GSS) (**GSS** or the **Company**) hereby gives notice to shareholders of the Company that, in relation to the Company's Notice of Annual General Meeting dated 16 November 2026 (**Notice**) in respect of an Annual General Meeting of Shareholders to be held at 9:00am (Sydney time), Monday, 16 November 2026 at Gadens, L29, 8 Chifley Square, Sydney NSW 2000 (**Meeting**), the Directors have determined to issue this addendum (**Addendum**) for the purposes set out below.

Defined terms in the Notice have the same meaning in this Addendum unless otherwise stated.

A. NEW RESOLUTION

The Notice is amended to include an additional resolution (**Resolution 4**) as set out in this Addendum in the business to be considered at the Meeting. The additional resolution is proposed to approve the issue of securities in connection with the proposed scheme of arrangement (**Proposed Scheme**) with Microba Life Sciences Limited (ASX: MAP) (**Microba**) in accordance with the requirements of ASX Listing Rule 7.1 (**Relevant Securities**). The below resolution is added to the Items of Business after Resolution 4.

As announced to market on 21 October 2026, GSS and Microba agreed to revise the terms of the Proposed Scheme as initially announced on 22 September 2026. Under the revised terms, Microba Shareholders will now hold 60% of the total GSS Shares on issue upon implementation (previously approximately 67%) while existing GSS Shareholders will hold 40% of the total GSS Shares on issue upon implementation.

Based on the number of Microba shares on issue as at the date of this Addendum Microba Shareholders will receive approximately 0.475 GSS Shares for every 1 Microba Share held (under the previous terms, Microba Shareholders would receive approximately 0.654 GSS Shares for every 1 Microba Share held), which equates to GSS issuing up to approximately 340.7 million Consideration Shares under the Proposed Scheme (under the previous terms, GSS would issue up to approximately 469 million GSS Shares).

The same ratio will be applied to the Microba Options on issue, to determine the number of GSS Options to be issued to Microba Optionholders.

Further details of the Proposed Scheme, including the revised terms agreed between GSS and Microba are set out in this Addendum.

B. OTHER INFORMATION

Replacement Proxy Form

Annexed to this Addendum is a replacement Proxy Form (**Replacement Proxy Form**). To ensure clarity of voting instructions by Shareholders on the Resolutions to be considered at the Meeting, Shareholders are advised that:

- (a) If you have already completed and returned the Proxy Form annexed with the Notice (**Original Proxy Form**) and you wish to change your original vote for Resolutions 1 to 3 or cast votes for the additional Resolution 4, **you must complete and return the Replacement Proxy Form**.
- (b) If you have already completed and returned the Original Proxy Form and **you do not wish to change your original vote for Resolutions 1 to 3 or vote on the additional Resolution 4, you do not need to take any action** as the earlier submitted Original Proxy Form will be accepted by the Company for Resolutions 1 to 3 unless you submit a Replacement Proxy Form. For the sake of clarity, the Company notes that if you do not lodge a Replacement Proxy Form, you will not have cast a vote on the additional Resolution 4.
- (c) If you have not yet completed and returned a Proxy Form and you wish to vote on the Resolutions in the Notice as supplemented by this Addendum, please complete and return the Replacement Proxy Form.

Chair's voting intentions

The Chair of the Meeting intends to vote all available proxies **FOR** Resolution 4.

Any directed proxies that are not voted on a poll at the Meeting will automatically default to the Chair of the Meeting, who is required to vote proxies as directed.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of Resolution 4 by or on behalf of Microba and any person who is expected to participate in, or who will obtain a material benefit as a result of, the Proposed Scheme or the proposed issue of the Relevant Securities (except a benefit solely by reason of being a holder of ordinary securities in the Company or Microba) or an associate of that person.

However, this does not apply to a vote cast in favour of Resolution 4 by:

- (a) a person as proxy or attorney for a person who is entitled to vote on Resolution 4, in accordance with the directions given to the proxy or attorney to vote in that way; or
- (b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on Resolution 4, in accordance with a direction given to the Chair to vote on Resolution 4 as the Chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on Resolution 4; and
 - (ii) the holder votes on Resolution 4 in accordance with directions given by the beneficiary to the holder to vote in that way.

Enquiries

Shareholders are invited to contact the Company Secretary, Sonya Tissera, at Sonya.Tissera@vistra.com if they have any queries in respect of the matters set out in this Addendum.

BY ORDER OF THE BOARD



Sonya Tissera
Company Secretary
23 October 2026

SUPPLEMENTARY BUSINESS OF THE MEETING

RESOLUTION 4: APPROVAL FOR ISSUE OF RELEVANT SECURITIES UNDER A SCHEME OF ARRANGEMENT WITH MICROBA

To consider and, if thought fit, pass the following as an **ordinary resolution** of Shareholders of the Company:

*“That, for the purposes of Listing Rule 7.1 and for all other purposes, the Shareholders approve the proposed issue of the Relevant Securities to the securityholders of Microba Life Sciences Limited ACN 617 096 652 (ASX: MAP) (**Microba**) as consideration under the proposed scheme of arrangement between the Company and Microba, on the terms and conditions set out in the Explanatory Memorandum accompanying the Notice of this Meeting.”*

The Board recommends that Shareholders vote **FOR** this resolution.

SUPPLEMENTARY EXPLANATORY STATEMENT

Background to Resolution 4

Resolution 4 seeks Shareholder approval for the issue of the Relevant Securities in connection with the proposed merger of the Company with Microba (**Proposed Merger**).

On 26 August 2026, the Company announced to ASX that it had entered into discussions with Microba regarding a potential merger to create a leading, scalable ASX-listed infectious disease diagnostics group. Microba's current portfolio, which is focused on gastrointestinal (**GI**) diagnostics, is complementary to the Company's existing GI offering.

On 22 September 2026, the Company further announced that GSS and Microba had reached agreement on the principal commercial terms of a merger between the two companies (**Merger Announcement**).

As set out in the Merger Announcement, the Company considers that the Proposed Merger represents a significant strategic opportunity for a number of reasons, including:

- **Complementary technologies:** Combines GSS's 3base® molecular diagnostics platform with Microba's metagenomic testing capabilities, broadening the group's offering across gastrointestinal and infectious disease diagnostics.
- **Expanded international platform:** Brings together GSS's hospital and laboratory customer base with Microba's clinician networks and pathology partnerships across Australia, the UK, Europe and the US.
- **Financial scale:** The combined group will have approximately \$29.6 million in aggregate FY2026 revenue, approximately \$30 million in cash and term deposits and net assets of approximately \$60.1 million.
- **Cost synergies:** Estimated annualised gross cost synergies of a minimum of \$2.5 - 3.0 million, principally from consolidating duplicated corporate functions and infrastructure.
- **Commercialisation pathways:** Provides additional pathways for commercialising GSS's diagnostic technologies by leveraging Microba's clinical testing operations and distribution relationships.
- **Accelerated path to cash-flow breakeven:** A more efficient combined operating structure may accelerate the combined group's pathway towards cash-flow breakeven.
- **All-scrip consideration:** Funded entirely through the issue of GSS securities with no cash consideration, preserving the combined group's cash resources.

As announced to market on 21 October 2026, GSS and Microba agreed to revise the terms of the Proposed Merger as initially announced on 22 September 2026. Under the revised terms, Microba Shareholders will now hold 60% of the total GSS Shares on issue upon implementation while existing GSS Shareholders will hold 40% of the total GSS Shares on issue upon implementation. Based on the number of Microba shares on issue as at the date of this

Addendum, Microba Shareholders will receive approximately 0.475 GSS Shares for every 1 Microba Share held, which equates to GSS issuing up to approximately 340.7 million Consideration Shares under the Proposed Merger.¹

To effect the Proposed Merger, the Company and Microba (subject to completing customary due diligence) propose to enter into a scheme implementation deed (**SID**), under which the Company proposes to acquire all of the issued securities in Microba by way of concurrent share and option schemes of arrangement (together, the **Proposed Scheme**).

As at 14 October 2026 (**Relevant Date**), Microba has the following securities on issue:

Class of securities as at the Relevant Date**	Number of securities as at the Relevant Date**
Shares	
Ordinary shares (quoted)	717,117,274
Total shares	717,117,274
Scheme Options	
MAPAQ options (unquoted)	80,555,423
MAPAR options (unquoted)	108,154,240
Total Scheme Options	188,709,663
Non-Scheme Options	
MAPAJ options (unquoted)	6,145,000
MAPAK options (unquoted)	2,000,000
MAPAN options (unquoted)	200,000
MAPAO options (unquoted)	10,070,514
MAPAP options (unquoted)	46,296,296*
MAPAS options (unquoted)	8,089,672
Total Non-Scheme Options	72,801,482

*The MAPAP options comprise a single option that is exercisable into a maximum of 46,296,296 Microba Shares together with up to 11,574,074 free-attaching Sonic Attaching Options (being 1 Sonic Attaching Option for every 4 Microba Shares issued upon the exercise of the MAPAP Options). For the purposes of calculating the maximum number of GSS Options that may be issued to replace the MAPAP options in connection with the Scheme and for which shareholder approval is being sought under this Resolution 4, the Company has assumed the maximum number of GSS Options may need to be issued, being 27,494,681 GSS Options (calculated by reference to the maximum potential Microba securities that may be issued on a fully diluted basis, being 57,870,370 underlying Microba securities).

**The Company notes that on 20 October 2026, MAP announced the Microba Placement (defined below), which will result in the issue of a maximum additional 50,625,000 Microba Shares. Please see comments below under the heading "Effect of Microba Placement" which outline the effect of the Microba Placement on the Proposed Scheme.

Under the Proposed Scheme, in consideration for the transfer of their Microba shares and Microba MAPAR Options and Microba MAPAQ Options to the Company, eligible Microba Shareholders and Optionholders will receive:

- in the case of Microba Shareholders, that number of GSS shares calculated by multiplying each Microba Share by the Scheme Formula, which results in the Microba Shareholders owning, in aggregate, 60% of GSS on Implementation of the Proposed Scheme (**Consideration Shares**). By way of illustration only by reference

¹ It is noted that the Microba Placement (defined below) will result in a decrease in the number of Consideration Securities and Additional Options to be received by each Microba Shareholder and each Microba Optionholder pursuant to the Scheme Formula, as is reflected below on page 7 given the Scheme Formula is applied on a per share Microba Share and Microba Option basis.

to the Microba Shares on issue as at the Relevant Date, the Scheme Formula equates to approximately 0.475 new GSS Shares for each Microba Share held; and

- in the case of holders of Microba MAPAR Option and Microba MAPAQ Option, that number of GSS options calculated by multiplying the number of Microba MAPAR Options and Microba MAPAQ Options held by the Scheme Formula, being the same transaction ratio as for the Scheme Shares (**Consideration Options**). The exercise price of the Consideration Options will be calculated by dividing the exercise price of the existing Microba MAPAR Options and Microba MAPAQ Options by the Scheme Formula. By way of illustration only, by reference to the Microba Shares on issue as at the Relevant Date, the Scheme Formula equates to approximately 0.475 new GSS Options for each MAPAR Option and Microba MAPAQ Option held, (collectively the **Consideration Securities**).

In connection with the Proposed Scheme, GSS also proposes to issue new GSS Options (**Additional Options**) to replace each Microba Option on issue other than the Microba MAPAR Options and Microba MAPAQ Options (**Non-Scheme Options**). Similarly, the number of Additional Options will be calculated by multiplying the number of Non-Scheme Options held by the Scheme Formula, whereby the exercise price of the Additional Options will be calculated by dividing the exercise price of the Non-Scheme Options by the Scheme Formula. By way of illustration only, by reference to the Microba Shares on issue as at the Relevant Date, the Scheme Formula equates to approximately 0.475 new GSS Options for each Non-Scheme Options held

Details of Relevant Securities for which shareholder approval is sought

Based on the number of MAP Shares and MAP Options on issue as at the Relevant Date, the number of Consideration Securities and Additional Options that the Company may issue in connection with the Proposed Merger (**Relevant Securities**) is as follows:

Class of securities	GSS Securities to be issued	Timing for issuance	Basis of determination
Consideration Shares	340,708,242 GSS Shares	Implementation of the Proposed Merger	By application of the Scheme Formula to the number of MAP Shares.
Consideration Options	89,657,494 GSS Options		By multiplying the number of Scheme Options by the Scheme Formula.
Additional Options	34,588,574 GSS Options		By multiplying the number of Non-Scheme Options by the Scheme Formula.
Additional Options	5,498,936 GSS Options	Upon the exercise of all applicable Additional Options to be issued to the holder of the MAPAP Options.	By multiplying the maximum number of Sonic Attaching Options (being 1 Sonic Option for every 4 MAPAP Option exercised) by the Scheme Formula.
Total Relevant Securities	470,453,246		

A further breakdown of the Consideration Options and Additional Options proposed to be issued is as follows:

MAP Options	Number of MAP Options ¹	Existing exercise price of MAP Options	Maximum number of GSS Options ²	New exercise price of GSS Options ³
Scheme Options				
MAPAQ options	80,555,423	\$0.1400	38,272,536	\$0.2947
MAPAR options	108,154,240	\$0.0625	51,384,958	\$0.1315

Subtotal	188,709,663		89,657,494	
Non-Scheme Options				
MAPAJ options	6,145,000	\$0.4532	2,919,539	\$0.9539
MAPAK options	2,000,000	\$0.6382	950,216	\$1.3433
MAPAN options	200,000	\$0.2715	95,021	\$0.5714
MAPAO options	10,070,514	\$0.3790	4,784,583	\$0.7977
MAPAP options	46,296,296	\$0.0900	27,494,681 ⁴	\$0.1894 ⁵
MAPAS options	8,089,672	\$0.0750	3,843,469	\$0.1579
Subtotal	72,801,482		40,087,509	
Total	261,511,145		129,745,003	

Notes:

1. The number of MAP Options is current as at the Relevant Date.
2. Subject to note 4 below, the number of GSS Options depicted in the above table represents the maximum number of GSS Options that may be issued and is calculated by multiplying the corresponding number of MAP Options by the Scheme Formula.
3. The new exercise price of GSS Options is calculated by dividing the existing exercise price of the corresponding MAP Option by the Scheme Formula.
4. As noted above in this Addendum, if all the MAPAP options are exercised, an additional 11,574,074 free-attaching Sonic Attaching Options will be issued. Accordingly, the corresponding maximum number of GSS Options to be issued in relation to the MAPAP options has been calculated on a fully-diluted basis, being 57,870,370 underlying Microba securities. Multiplying this amount by the Scheme Formula equates to 27,494,681 new GSS Options.
5. This represents the exercise price for the new GSS Options relating to the MAPAP options only. The exercise price for new GSS Options relating to the Sonic Attaching Options will be calculated as a 20% premium to that exercise price.

Shareholders should note that the above number of Relevant Securities is an estimate only and represents the maximum number of GSS Equity Securities to be issued. Namely, the number of Relevant Securities that will be issued depends on the number of Microba Shares and Microba Options on issue as at the Scheme Record Date, and therefore, is subject to change.

Effect of Microba Placement

On 20 October 2026, Microba announced that it had received firm commitments to raise approximately \$2.025 million (before costs) through a two-tranche placement (**Microba Placement**). As part of the Microba Placement, Microba will issue 50,625,000 new shares at \$0.04 per share, in the following tranches:

- 25,625,000 new Microba Shares, raising \$1.025 million expected to settle on 26 October 2026, issued under Microba's existing placement capacity (**Tranche 1**); and
- 25,000,000 new Microba Shares raising \$1 million (**Tranche 2**), subject to satisfaction of the following conditions:
 - all necessary shareholder approvals being obtained at a general meeting of Microba, expected to be held in December 2026; and
 - GSS obtaining all shareholder approvals necessary for the Proposed Merger.

The reference to Microba Shares on issue at the Relevant Date refers to the 717,117,274 shares on issue as at 21 October 2026, and therefore does not include any shares issued under the Microba Placement. The Microba Placement will increase the number of Microba Shares on issue at the Scheme Record Date (assuming no other Microba Shares are issued before the Scheme Record Date) to 767,742,274 Microba Shares.

The Microba Placement will not dilute GSS Shareholders, due to the non-dilutive operation of the Scheme Formula which preserves an outcome whereby existing GSS Shareholders will hold 40% of the GSS Shares on issue following implementation of the merger. The issue of further Microba Shares pursuant to the Microba Placement reduces the number of GSS Securities issued per Microba Share or Microba Option held.

As a result, the maximum number of Consideration Shares to be issued remains at 340,708,242 following the Microba Placement. However, the number of Consideration Options will decrease, as illustrated in the following table:

	Relevant Date (pre-Microba Placement)	Post-Microba Placement
Microba Shares on issue	717,117,274	767,742,274
GSS Shares per Microba Share (approx.)	0.475	0.444
Consideration Shares issued	340,708,242	340,708,242
Maximum Consideration Options and Additional Options issued	129,745,003	121,189,607

The total number of Consideration Options and Additional Options reduces because of the impact of the Microba Placement on the Scheme Formula, which means that post the Microba Placement (which did not include the issue of any Microba Options), the ratio will also reduce for the Microba Options, from 0.4751 GSS Options per Microba Option to 0.444 GSS Options per Microba Option.

Accordingly, this Resolution 4 seeks Shareholder approval for the proposed issue of up to 340,708,242 GSS Shares and 129,745,003 GSS Options pursuant to the Proposed Merger.

Application of Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period (**15% Placement Capacity**).

The proposed issue of the Relevant Securities (**Relevant Issue**) does not fall within any of these exceptions and exceeds the 15% limit in Listing Rule 7.1. It therefore requires the approval of the Company's Shareholders under Listing Rule 7.1. Resolution 4 seeks the Shareholder approval for the Relevant Issue under and for the purposes of Listing Rule 7.1.

If Resolution 4 is passed, the Company will be able to proceed with the Relevant Issue and, subject to the Proposed Scheme proceeding including all relevant conditions precedent being satisfied or waived, can issue the Relevant Securities in accordance with the SID. In addition, the Relevant Securities will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 4 is not passed, the Company will not be able to proceed with the Relevant Issue and the Company and Microba will not be able to proceed with the Proposed Scheme in its current form. Insofar as the Company still proposes to pursue a merger with Microba, it will need to seek approval from Shareholders again or, alternatively, attempt to proceed on different terms to those currently contemplated.

Specific information required by Listing Rule 7.3

The Company provides the below information with respect to Resolution 4 pursuant to Listing Rule 7.3.

The Company notes that the parties are yet to enter into binding documentation. However, the terms of the Proposed Scheme will be finalised and agreed between the parties and recorded in the SID.

Listing Rule	Required Disclosure
7.3.1	The Relevant Securities will be issued to the securityholders of Microba who are eligible to receive Consideration Securities under the Proposed Scheme as well as to relevant holders of Microba Options. The names of the particular allottees are not yet known but will be determined in accordance with the Proposed Scheme. The Company confirms that: • none of the proposed recipients of the Relevant Securities is a substantial shareholder of the Company for the purposes of section 7.2 of ASX Guidance Note 21. • the following recipients of the Relevant Securities are expected to be related parties of the Company for the purposes of section 7.2 of ASX Guidance Note 21: ○ Pasquale Rombola, existing director of Microba and shareholder and Optionholder of Microba, and anticipated to become a Director of GSS on completion of the Proposed Scheme; ○ Stephane Chatonsky, existing director and anticipated shareholder of Microba (following completion of the Microba Placement), and anticipated to become a Director of GSS on completion of the Proposed Scheme; and ○ Jacqueline Fernley, existing director of Microba and Optionholder of Microba, and anticipated to become a Director of GSS on completion of the Proposed Scheme. The Company will rely on exception 5 of in ASX Listing Rule 10.12 for the issue of Relevant Securities to each of Pasquale Rombola and Jacqueline Fernley, being an issue of securities under a merger by way of scheme of arrangement under Part 5.1 of the Corporations Act.
7.3.2	Subject to the Company obtaining shareholder approval for this Resolution 4, the Company proposes to issue the Relevant Securities, determined in accordance with the Scheme Formula and as otherwise set out above. The maximum number of Relevant Securities that the Company may issue is as follows: • 340,708,242 GSS Shares; and • 129,745,003 GSS Options.
7.3.3	The Proposed Scheme will involve the issue of the Consideration Shares and the Consideration Options. The Additional Options will be issued adjunct to the Proposed Scheme. A summary of the material terms of the issue of the Consideration Options and Additional Options is set out in Schedule 3.
7.3.4	As the Proposed Scheme will involve GSS issuing more than 100% of its current issued shares to Microba shareholders in consideration for acquiring the Microba Securities, the Proposed Scheme constitutes a “reverse takeover” for the purposes of Listing Rule 19.12. Accordingly, if Resolution 4 is passed at the AGM, the Relevant Securities will be issued by 16 May 2027, being no more than 6 months after the date of the AGM.
7.3.5	The Company will not receive any cash funds in exchange for the issue of the Relevant Securities. The Relevant Securities will be issued as consideration for the transfer (or

Listing Rule	Required Disclosure
	cancellation) of relevant issued shares and options in Microba to the Company under the terms of the SID.
7.3.6	The Company proposes to issue the Relevant Securities as consideration for the acquisition (or cancellation) of relevant issued shares and options in Microba pursuant to the Proposed Scheme.
7.3.7	Subject to the Shareholders approving the issue of the Relevant Securities under Resolution 4, the Company will enter into a SID with Microba. A summary of the key terms and conditions of the SID is set out in Schedule 2.
7.3.8	The Relevant Securities are proposed to be issued to relevant holders of Microba shares and options under the Proposed Scheme and if issued, will comprise more than 100% of the current capital of the Company. Accordingly, the Proposed Scheme constitutes a “reverse takeover” for the purposes of Listing Rule 19.12. A summary of the material information relating to the Proposed Scheme is set out below.
7.3.9	Please refer to the voting exclusion statement for Resolution 4 in section C (“Other Information”).

Reverse Takeover Information

As stated above, the Proposed Scheme will constitute a “reverse takeover” for the purposes of the Listing Rules. The Company therefore provides the following information with respect to Resolution 4.

Requirement	Information
Identity of reverse takeover target	Microba Life Sciences Limited (ASX: MAP)
Principal activities and jurisdiction	Microba was admitted to the official list of the ASX on 5 April 2022. Since that time, it has operated as a precision microbiome company in Australia focused on analysing the human gut microbiome using advanced technology to improve health and developing novel therapies from its globally leading Microbiome Discovery Database, operating under two distinct business divisions, namely its: • clinical microbiome diagnostics division; and • clinical stage therapeutics division. As part of the growth of its Diagnostics Division, in December 2023 Microba acquired UK registered Invivo Clinical Ltd. Following this acquisition, the Diagnostics Division was broadened into the diagnostics and supplements division.
Business model, key dependencies and key risks	Business model Microba describes itself as creating a new diagnostic category in clinical microbiome testing. During FY26, Microba completed the planned phase-out of discontinued legacy products so that the business is now centred on core testing products designed for scale, and it paused all internal therapeutics research and development in favour of a capital-light partnering strategy. Diagnostics and Supplements Division: Microba’s core testing products are gut microbiome tests ordered by healthcare practitioners and analysed at Microba’s consolidated Brisbane-based laboratory, which uses DNA sequencing infrastructure

Requirement	Information
	including an Illumina NovaSeqX Plus sequencing machine. The principal products are: • Microba Microbiome Explorer™ – Microba’s core test, sold to practitioners in Australia and the United Kingdom. Q4 FY26 volumes were a record 5,311 tests in Australia and 825 tests in the United Kingdom. • Microba MetaPanel™ – sold in partnership with Sonic Healthcare Limited (Sonic) with a focus on gastroenterology specialists, with clinical validation published reporting greater than 99% median specificity and 91% median sensitivity. • Microba GI Navigator – a premium product powered by Microba’s proprietary Clinical Logic Engine, designed for people living with an unresolved gastrointestinal disorder and expected to launch in October 2026. It is intended to extend Microba’s serviceable market to medical doctors, and the first 35 sales have been achieved through an early-access program. • Supplements – own-brand Invivo supplements (led by PHGG prebiotic fibre, with a subscription offering of more than 1,000 subscribers), alongside distributed Designs For Health products, revenue from which is being deliberately reduced. Since November 2025 Microba has also contracted enterprise-style accounts with healthcare clinics, with 43 accounts signed (selling 5,606 tests) and a key-account pipeline of more than 175 targets. Outside Australia and the United Kingdom, Microba maintains distribution partnerships with SYNLAB and Genova to support future European and United States testing expansion. Testing revenue is recognised when the final report is delivered to the practitioner rather than when a kit is ordered and paid for. At 30 June 2026 Microba held \$1.79 million of Microbiome Explorer deferred revenue. Therapeutics Division: Microba holds live biotherapeutic intellectual property across inflammatory bowel disease, autoimmune disease, oncology and allergy. Its lead asset, MAP-315, is a Phase 2-ready oral-capsule live biotherapeutic for mild-to-moderate ulcerative colitis. Microba commenced a formal partnering campaign in July 2026 with Boston-based advisors. Partnering pathways include licensing arrangements and non-dilutive, asset-specific equity structures, and Microba ascribes no value to a therapeutics transaction in its funding plans. Financial profile: In FY26 Microba generated revenue from contracts with customers of \$14.76 million (down 6%, reflecting the legacy phase-out), comprising continuing product revenue of \$12.7 million (up 53%) and core testing revenue of approximately \$8.6 million (up 92%) on 22,418 core tests (up 78%). Revenue was earned principally in Australia (\$7.04 million) and the United Kingdom (\$6.09 million). Gross margin was 47.6%, total expenses were \$29.92 million, the statutory loss after tax was \$20.72 million and net operating cash outflow was \$12.37 million. Microba held cash of \$7.95 million at 30 June 2026. Microba is targeting whole-company cash flow break-even, on a run-rate basis, in calendar year 2027, supported by a cost-streamlining program targeting approximately \$7 million per annum of reductions that is to be fully implemented in H1 FY27. Key dependencies • Access to capital: Microba is not yet cash flow positive and relies on external capital until revenues scale sufficiently. It raised \$13.0 million (gross) during FY26 with the support of its major shareholders. • R&D Tax Incentive: Microba relies on cash inflows under the Commonwealth R&D Tax Incentive. Its FY26 refund has been advanced under a secured facility

Requirement	Information
	with Radium Capital (approximately \$2.05 million at 16.00% per annum, maturing 31 January 2027). • Sonic Healthcare: Sonic, Microba's largest shareholder, is also Microba's partner for MetaPanel. • Clinician adoption and the enterprise-clinic channel: growth depends on continued clinician education and clinical evidence, and on the maturing of enterprise-clinic accounts, which concentrate revenue and extend payment terms. • GI Navigator and the cost program: the October 2026 launch of GI Navigator and full delivery of the approximately \$7 million cost-reduction program both underpin the calendar year 2027 break-even objective. • Laboratory operations and supply chain: testing depends on Microba's Brisbane laboratory, its sequencing equipment and a consistent supply of consumables and reagents, in some cases from limited sources. • Intellectual property, data and people: Microba relies on its proprietary measurement methods, bioinformatics intellectual property, accreditation and clinical-grade dataset, and on a smaller post-restructure team with specialised bioinformatics, engineering, scientific and commercial capability. Key risks The FY26 Annual Report identifies the following material business risks, which it notes is a condensed and non-exhaustive overview: • Liquidity and capital raising: Microba relies on external capital until revenues scale. Its financial statements note a material uncertainty that may cast significant doubt on its ability to continue as a going concern should its planned initiatives not materialise, and adverse market conditions could make raising capital more challenging and/or more dilutive. • Execution of the cost reduction program: shortfalls in delivery or timing, or reductions that impair revenue-generating capability, would extend the path to break-even. • New product launch and commercialisation: the GI Navigator launch and expansion to medical doctors carry risks of delay, slower clinician adoption, pricing pressure and additional evidence requirements. • Key partners and customer concentration: loss of, or adverse changes with, Sonic or a significant enterprise-clinic account could affect revenue and growth. • Conversion of kits sold into revenue: recognition of deferred revenue depends on patients returning samples, which Microba only partly influences; unreturned kits expire, which would defer or reduce revenue and cash conversion. • Market development and adoption: adoption of a new diagnostic category depends on clinician education, clinical evidence and, over time, reimbursement, and may be slower than anticipated. FY26 core test volumes (22,418) were below guidance of more than 24,000 and regional break-even in Australia and the United Kingdom was not achieved. • Regulatory and compliance: changes to healthcare, privacy, data protection and medical testing laws or standards, or non-compliance, could result in liabilities, fines, reputational damage and delays. • Competition: the microbiome industry is evolving rapidly and attracting global competitors, which may pressure pricing, margins and market share. • Intellectual property and intangible assets: patent outcomes, infringement or competitor challenges could affect Microba's position. Microba carries goodwill of \$9.2 million (relating to the Invivo acquisition) and other intangibles whose recoverable amounts depend on future performance, and recognised a \$0.75 million impairment in FY26.

Requirement	Information
	• Therapeutics partnering and clinical trials: the value of the therapeutic assets depends on securing a partnering transaction, the timing and terms of which are uncertain, and adverse trial results for Microba or its peers could reduce their attractiveness. • Key personnel and supply chain: loss of key personnel, or disruption to the supply of laboratory equipment, consumables and reagents, could affect execution, throughput and cost of goods. • Foreign exchange and pricing: Microba earns revenue and holds balances in multiple currencies, including GBP (FY26 included a \$1.51 million non-cash foreign currency loss), and competitive pricing pressure, customer mix or enterprise pricing could reduce margin per test. • New jurisdictions and cybersecurity: expansion into new markets exposes Microba to differing regulatory, reimbursement and commercial conditions, and as a holder of sensitive personal health data, a cybersecurity breach could result in regulatory action, remediation costs and reputational damage.
Audited accounts	Microba's FY26 Annual Report containing its audited accounts is annexed to this Addendum at Annexure A.
Regulatory approvals, waivers or other material conditions that must be satisfied	The reverse takeover will be conditional upon: • the Company obtaining approval from its shareholders for the issue of the Relevant Securities at the AGM; and • satisfaction of each of the Scheme Conditions (set out in Schedule 2).
Likely effect of the proposed issue and the reverse takeover on the entity	Information regarding the likely effect of the Proposed Scheme on the consolidated total assets, total equity interests, net revenue, EBITDA and profit before tax is set out in Schedule 4.
Issued capital before and after the reverse takeover	Information regarding the effect of the Proposed Scheme on the issued capital of the Company is set out in Schedule 4.
Fundraising	The Company is not proposing to raise any funds in connection with the Proposed Scheme.
Acquisition of voting power of 20% or more	It is not anticipated that any Microba shareholder will obtain a voting power of 20% or more in the Company on completion of the Proposed Scheme.
Changes to senior board or management	It is proposed that the board of the merged entity will be comprised of six directors, comprising the three existing Directors of GSS together with three additional appointees of Microba, being Pasquale Rombola, Jacqueline Fernley and Stephane Chatonsky. The Board of the merged entity will also conduct a review of key senior management and operational roles to ensure the combined group has the appropriate leadership, capabilities and organisational structure.
Implementation timetable	An indicative timeline of the Proposed Scheme is set out in Schedule 5.

The Board **unanimously recommends that Shareholders VOTE FOR Resolution 4.**

All Correspondence to:

✉ **By Mail** Boardroom Pty Limited
GPO Box 3993
Sydney NSW 2001 Australia

📠 **By Fax:** +61 2 9290 9655

💻 **Online:** www.boardroomlimited.com.au

☎ **By Phone:** (within Australia) 1300 737 760
(outside Australia) +61 2 9290 9600

YOUR VOTE IS IMPORTANT

For your vote to be effective it must be recorded **before 9:00am (Sydney time) on Saturday, 14 November 2026.**

🖥 TO APPOINT A PROXY ONLINE

📱 BY SMARTPHONE

STEP 1: VISIT <https://www.votingonline.com.au/gssagm2026>

STEP 2: Enter your Postcode OR Country of Residence (if outside Australia)

STEP 3: Enter your Voting Access Code (VAC):



Scan QR Code using smartphone
QR Reader App

TO VOTE BY COMPLETING THE PROXY FORM

STEP 1 APPOINTMENT OF PROXY

Indicate who you want to appoint as your Proxy.

If you wish to appoint the Chair of the Meeting as your proxy, mark the box. If you wish to appoint someone other than the Chair of the Meeting as your proxy please write the full name of that individual or body corporate. If you leave this section blank, or your named proxy does not attend the meeting, the Chair of the Meeting will be your proxy. A proxy need not be a securityholder of the company. Do not write the name of the issuer company or the registered securityholder in the space.

Appointment of a Second Proxy

You are entitled to appoint up to two proxies to attend the meeting and vote. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by contacting the company's securities registry or you may copy this form.

To appoint a second proxy you must:

- complete two Proxy Forms. On each Proxy Form state the percentage of your voting rights or the number of securities applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded.
- return both forms together in the same envelope.

STEP 2 VOTING DIRECTIONS TO YOUR PROXY

To direct your proxy how to vote, mark one of the boxes opposite each item of business. All your securities will be voted in accordance with such a direction unless you indicate only a portion of securities are to be voted on any item by inserting the percentage or number that you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on a given item, your proxy may vote as he or she chooses. If you mark more than one box on an item for all your securities your vote on that item will be invalid.

Proxy which is a Body Corporate

Where a body corporate is appointed as your proxy, the representative of that body corporate attending the meeting must have provided an "Appointment of Corporate Representative" prior to admission. An Appointment of Corporate Representative form can be obtained from the company's securities registry.

STEP 3 SIGN THE FORM

The form **must** be signed as follows:

Individual: This form is to be signed by the securityholder.

Joint Holding: where the holding is in more than one name, all the securityholders should sign.

Power of Attorney: to sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director who is also the Sole Company Secretary, this form should be signed by that person. **Please indicate the office held by signing in the appropriate place.**

STEP 4 LODGEMENT

Proxy forms (and any Power of Attorney under which it is signed) must be received no later than 48 hours before the commencement of the meeting, therefore by **9:00am (Sydney time) on Saturday, 14 November 2026**. Any Proxy Form received after that time will not be valid for the scheduled meeting.

Proxy forms may be lodged using the enclosed Reply Paid Envelope or:

- 🖥 **Online** <https://www.votingonline.com.au/gssagm2026>
- 📠 **By Fax** + 61 2 9290 9655
- ✉ **By Mail** Boardroom Pty Limited
GPO Box 3993,
Sydney NSW 2001 Australia
- 👤 **In Person** Boardroom Pty Limited
Level 8, 210 George Street
Sydney NSW 2000 Australia

Attending the Meeting

If you wish to attend the meeting please bring this form with you to assist registration.

☐

Your Address
This is your address as it appears on the company's share register. If this is incorrect, please mark the box with an "X" and make the correction in the space to the left. Securityholders sponsored by a broker should advise their broker of any changes.
Please note, you cannot change ownership of your securities using this form.

PROXY FORM

STEP 1 APPOINT A PROXY

I/We being a member/s of **Genetic Signatures Limited** (Company) and entitled to attend and vote hereby appoint:

☐

 the **Chair of the Meeting (mark box)**
OR if you are **NOT** appointing the Chair of the Meeting as your proxy, please write the name of the person or body corporate (excluding the registered securityholder) you are appointing as your proxy below

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting as my/our proxy at the Annual General Meeting of the Company to be held at the **Gadens, Level 29, 8 Chifley Square, Sydney NSW 2000 on Monday, 16 November, 2026 at 9:00am (Sydney time)** and at any adjournment of that meeting, to act on my/our behalf and to vote in accordance with the following directions or if no directions have been given, as the proxy sees fit.

The Chair of the Meeting is authorised to exercise undirected proxies on remuneration related matters: If I/we have appointed the Chair of the Meeting as my/our proxy or the Chair of the Meeting becomes my/our proxy by default and I/we have not directed my/our proxy how to vote in respect of **Resolution 1** I/we expressly authorise the Chair of the Meeting to exercise my/our proxy in respect of these Resolutions even though **Resolution 1** is connected with the remuneration of a member of the key management personnel for the Company.

The Chair of the Meeting will vote all undirected proxies in favour of all Items of business (**including Resolution 1**). If you wish to appoint the Chair of the Meeting as your proxy with a direction to vote against, or to abstain from voting on an item, you must provide a direction by marking the 'Against' or 'Abstain' box opposite that resolution.

STEP 2 VOTING DIRECTIONS

* If you mark the Abstain box for a particular item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your vote will not be counted in calculating the required majority if a poll is called.

		For	Against	Abstain*
Resolution 1	Adoption of the Remuneration Report	☐	☐	☐
Resolution 2	Re-election of Director – Dr Jenny Harry	☐	☐	☐
Resolution 3	Re-election of Director – Mrs Anne Lockwood	☐	☐	☐
Resolution 4	Approval for the Issue of Relevant Securities Under a Scheme of Arrangement with Microba	☐	☐	☐

STEP 3 SIGNATURE OF SECURITYHOLDERS

This form must be signed to enable your directions to be implemented.

Individual or Securityholder 1

Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

Director / Company Secretary

Contact Name..... Contact Daytime Telephone..... Date / /2026

SCHEDULE 1: GLOSSARY

In this Addendum, capitalised terms have the meanings given to them in the Notice, save for the following expressions which have the following meanings:

“Addendum”	means this addendum to the Notice.
“Consideration Options”	has the meaning given to that term on page 4 of this Addendum.
“Consideration Securities”	has the meaning given to that term on page 4 of this Addendum.
“Consideration Shares”	has the meaning given to that term on page 4 of this Addendum.
“Effective Date”	means the coming into effect, under subsection 411(10) of the Corporations Act, of the order of the Court made under paragraph 411(4)(b) of the Corporations Act in relation to the Proposed Scheme.
“Explanatory Memorandum”	means the explanatory memorandum accompanying this Addendum.
“GSS Option”	means an option to acquire a GSS Share.
“GSS Share”	means a fully paid ordinary share in the capital of the Company.
“Implementation”	means implementation of the Proposed Scheme, being the transfer of all of the Scheme Shares and Scheme Options to the Company, and issue of the Consideration Securities to the holders of Microba Securities.
“Microba MAPAR Options”	means Microba Options with the ASX security code MAPAR.
“Microba MAPAQ Options”	means Microba Options with the ASX security code MAPAQ.
“Microba Option”	means an option to acquire a Microba Share.
“Microba Optionholder”	means the holder of a Microba Option.
“Microba Placement”	has the meaning given to that term on page 6 of this Addendum.
“Microba Securities”	means the Scheme Shares and the Scheme Options.
“Microba Share”	means a fully paid ordinary share in the capital of Microba.
“Microba Shareholder”	means the registered holder of a Microba Share.
“Notice”	means the Company’s Notice of Annual General Meeting dated 16 October 2026.
“Non-Scheme Option”	means a Microba Option on issue other than the Microba MAPAR Options and the Microba MAPAQ Options.
“Proposed Scheme”	means the proposed acquisition of all of the Microba Shares and Scheme Options by the Company pursuant to: (a) a share scheme of arrangement; and (b) an option scheme of arrangement.

“Relevant Securities”	has the meaning given to that term on page 5 of this Addendum and includes: (a) the Consideration Shares; (b) the Consideration Options; (c) the Additional Options; and (d) any further GSS Options that may subsequently become issuable in connection with the Sonic Attaching Option.
“Scheme Formula”	means the formula that the Company will use for the purpose of calculating the number of Consideration Securities and Additional Options to be issued to Microba Shareholders and Microba Optionholders, which is as follows: $N = \frac{0.6 \times (\frac{A}{0.4})}{B}$ Where: <i>N is the number of Consideration Securities and Additional Options to be issued to the Microba Shareholders and Microba Optionholders for each Microba Share and Microba Option held as at the Scheme Record Date, respectively;</i> <i>A is the total number of GSS Shares on issue at the Scheme Record Date; and</i> <i>B is the total number of Microba Shares on issue at the Scheme Record Date.</i>
“Scheme Options”	means the issued Microba MAPAR Options and Microba MAPAQ Options that the Company proposes to acquire under the Proposed Scheme.
“Scheme Record Date”	means 7:00pm on the second business day after the Effective Date or such other time and date as agreed by the Company and Microba in writing.
“Scheme Shares”	means the issued shares in Microba that the Company proposes to acquire under the Proposed Scheme.
“Sonic Options”	means the Microba Options with the ASX security code MAPAP (please refer to the summary of these options in section C of Schedule 3 to this Addendum).
“Sonic Attaching Options”	means the free-attaching Microba Options to be issued upon the exercise of the Sonic Options, on the basis of 1 Sonic Attaching Option for every 4 Sonic Options exercised.
“SID”	means the scheme implementation deed that the Company proposes to enter into with Microba.

SCHEDULE 2: MATERIAL TERMS OF THE SCHEME IMPLEMENTATION DEED

While GSS and Microba have yet to execute binding documentation in relation to the Proposed Scheme, GSS and Microba have significantly progressed negotiation of the Scheme Implementation Deed (**SID**) pursuant to which the Proposed Scheme will be implemented.

If the Shareholders approve Resolution 4, subject to completing customary due diligence, GSS and Microba propose to enter into the SID. A summary of the material terms and conditions that the parties have agreed in-principle to include in the SID is provided below. Shareholders will be notified in the event that there are any material changes to the below terms upon execution of the SID.

Material term	Description
Parties	The Bidder is Genetic Signatures Limited, and the Target is Microba Life Sciences Limited.
Transaction structure	The Company proposes to acquire all Scheme Shares and Scheme Options of Microba via a scheme of arrangement under Part 5.1 of the Corporations Act.
Scheme Consideration	The consideration to be provided by the Company to Microba Shareholders and Microba Optionholders for the transfer of their Microba Securities pursuant to the Scheme is as follows (Consideration Securities): (a) in the case of Microba Shareholders, such number of Consideration Shares as is calculated using the Scheme Formula; and (b) in the case of holders of Scheme Options, such number of Consideration Options calculated by multiplying each Microba MAPAR Option and Microba MAPAQ Option by the Scheme Formula. The exercise price of the Consideration Options will be calculated by dividing the exercise price of the existing Microba MAPAR Options and Microba MAPAQ Options by the Scheme Formula. In addition to the Scheme Consideration, the Company may also issue new GSS Options (Additional Options) to replace each Microba Option on issue other than the Microba MAPAR Options and Microba MAPAQ Options (Non-Scheme Options), calculated by multiplying each Non-Scheme Option by the Scheme Formula. The legal mechanism under which the Additional Options will be deeds between the Company and the individual Optionholders. The terms of the deed will provide that the Company will issue the relevant number of Additional Options in consideration for the Option holders either consenting to the cancellation of their options in MAP or them transferring the options to the Company. Whilst the Additional Options will not be dealt with under an option scheme, their treatment and the way they are dealt with will be agreed under the terms of the SID. As noted above, based on the number of MAP Shares and MAP Options on issue as at the Relevant Date, the maximum number of Consideration Securities and Additional Options the Company may issue is as follows: • 340,708,242 GSS Shares; and • 129,745,003 GSS Options.
Conditions precedent	A summary of the conditions, to which the Scheme is expected to be subject, includes the following:

Material term	Description
	(a) (Scheme shareholder approval) Microba Shareholders approve the Scheme by the majorities required under the Corporations Act. (b) (Court approval of Scheme) The Court approves the Scheme in accordance with section 411(4)(b) of the Corporations Act, either unconditionally or with modifications or conditions consented to by the Company (acting reasonably). (c) (Regulatory approvals) All consents, waivers, exemptions, declarations and approvals that are required by law, or by any regulatory authority to implement the Scheme are granted. (d) (No restraint) No judgement, decree, statute, law, ordinance, rule or regulation that prohibits, materially restricts, makes illegal, restrains or materially delays the completion of the Scheme is in effect. (e) (Independent Expert's Report) the Independent Expert's Report concludes that the Scheme is in the best interests of Microba Shareholders (other than any Excluded Shareholders) and the Option Scheme is in the best interests of holders of Scheme Options (other than any Excluded Optionholders) on or before the date on which the Scheme Booklet is registered with ASIC and the Independent Expert does not change or publicly withdraw that conclusion prior to the Second Court Date. (f) (No Target Material Adverse Change) No material adverse change occurs in relation to Microba, being an event, matter, change or circumstance that has the effect of diminishing the net tangible assets of Microba by at least 20% by reference to the net tangible assets of Microba as at 30 September 2026. (g) (Financial performance) each party maintains an acceptable level of financial performance, the terms of which are to be negotiated and will be detailed in the SID. (h) (No Target Prescribed Occurrence) No Prescribed Occurrence occurs in relation to Microba, being a breach of customary restrictions on the conduct of Microba's business prior to implementation of the Scheme. (i) (Target Warranties) The warranties provided by Microba under the SID are true and correct in all material respects as at the time they are given or made. (j) (Bidder Warranties) The warranties provided by the Company under the SID are true and correct in all material respects as at the time they are given or made. (k) (No Bidder Material Adverse Change) No material adverse change occurs in relation to the Company, being an event, matter, change or circumstance that has the effect of diminishing the net tangible assets of the Company by at least 20% relative to the net tangible assets of the Company as at 30 September 2026; (l) (No Bidder Prescribed Occurrence) No Prescribed Occurrence occurs in relation to the Company, being a breach of customary restrictions on the

Material term	Description
	conduct of the Company's business prior to implementation of the Scheme. (m) (Bidder Shareholder approval) The Company receives all required approvals from its shareholders for the issue of the Scheme Consideration, for the purposes of ASX Listing Rule 7.1. (n) (Option Scheme shareholder approval) Microba Optionholders approve the Option Scheme by the majorities required under the Corporations Act. (o) (Court approval of Option Scheme) The Court approves the Option Scheme in accordance with section 411(4)(b) of the Corporations Act, either unconditionally or with modifications or conditions consented to by the Company (acting reasonably). (p) (Target Material Contracts) between the date of the SID and 8.00am on the Second Court Date, no counterparty to a Target Material Contract has given notice in writing to the relevant member of the Target Group of its intention to: ○ terminate all the Target Material Contracts that counterparty has in place with the Target Group in their entirety; or ○ terminate one or more Target Material Contracts that counterparty has in place with the Target Group where such termination would have the impact of reducing the aggregate revenues associated with that counterparty by more than 20%; (q) (Company Material Contracts) between the date of the SID and 8.00am on the Second Court Date, no counterparty to a Company Material Contract has given notice in writing to the relevant member of the Company Group of its intention to: ○ terminate all the Company Material Contracts that counterparty has in place with the Company Group in their entirety; or ○ terminate one or more Company Material Contracts that counterparty has in place with the Company Group where such termination would have the impact of reducing the aggregate revenues associated with that counterparty by more than 20%; (r) (Additional Options treaties) by 8.00am on the Second Court Date holders of the Additional Options either consenting to the cancellation of their Microba Options or transferring their Microba Options to the Company on terms acceptable to the Company acting reasonably.
Microba Board Recommendation	The SID will require Microba to ensure that the Scheme Booklet states that: (a) each Microba Director considers the Scheme to be in the best interests of holders of Microba Shares and Scheme Options and recommends that such holders vote in favour of the Scheme; and

Material term	Description
	(b) each Microba Director intends to cause any Microba Shares and Scheme Options in which it has a Relevant Interest to be voted in favour of the Scheme, in the absence of a superior proposal. Microba must ensure that the Microba Directors collectively and individually do not change, withdraw or modify their recommendation or voting intention unless: (a) Microba has received (other than as a result of a breach of the exclusivity provisions under the SID) a competing proposal which is or could reasonably be expected to lead to a superior proposal; or (b) the Independent Expert concludes in the Independent Expert's Report that the Scheme is not in the best interests of the Microba Shareholders or that the Option Scheme is not in the best interests of holders of Scheme Options (other than where the conclusion is due to the existence of a Competing Proposal), and Microba has complied with its exclusivity obligations under the SID, including ensuring that all of the Company's matching rights have been exhausted.
Conduct of business	The SID will require Microba to carry on the business and operations of the Microba Group in the ordinary and usual course of business.
Representations and warranties	The SID will contain customary representations and warranties provided by each of Microba and the Company to each other.
Exclusivity	The SID will contain a number of deal protection mechanisms including the following: (a) exclusivity arrangements; (b) restriction on the parties negotiating or providing due diligence access in respect of a competing proposal; (c) matching rights to the Company to match a counterproposal given to Microba; and (d) break fees. Microba is exempt from certain exclusivity restrictions (including the no shop, no talk, no due diligence and notification obligations) to the extent necessary to take action with respect to a genuine, unsolicited Competing Proposal, provided that the Microba Board has first determined in good faith, after consulting with its financial and legal advisers, that the proposal is or could reasonably be expected to lead to a Superior Proposal and that compliance with the exclusivity restrictions would constitute, or be likely to constitute, a breach of Microba Board's fiduciary or statutory duties.
Break fee	Microba has agreed to pay the Company a break fee (capped at \$188,000, inclusive of GST) if any of the following events occur: (a) a competing proposal for Microba is publicly announced on or before the Second Court Date and, within 12 months from the date of that public

Material term	Description
	announcement, the competing proposal is implemented or completed, substantially in the terms described in the public announcement; (b) any Microba Director fails to make their recommendation, withdraws or adversely changes their recommendation or makes a public statement indicating that they no longer recommend the Scheme or otherwise publicly recommends, supports or endorses a competing proposal, in each case other than in circumstances where: ○ a Court or a regulatory authority requires a Microba Director to abstain or withdraw from making that recommendation; ○ the Independent Expert concludes that the Scheme is not in the best interests of the holders of Microba Shares or Scheme Options (other than where the reason for that opinion is a superior proposal); ○ that act results from any matter or thing giving Microba the right to terminate the SID. The Company has agreed to pay Microba a break fee (capped at \$188,000, inclusive of GST) if any of the following events occur: (a) one or more Directors, fail to recommend that GSS shareholders vote in favour of all resolutions relating to the Transaction contained in the Notice of Meeting; or (b) all conditions have been satisfied or waived in accordance with the SID and the Company does not pay or procure the payment of the Scheme Consideration in accordance with the terms and conditions of the SID.
Board changes	On the Implementation Date, Microba must appoint Company nominees to the Microba Board and procure the resignation of specified existing directors. Reciprocal provisions apply for the Company Board. It is proposed that the board of the merged entity will be comprised of six directors, comprising the three existing Directors of GSS together with three additional appointees of Microba, being Pasquale Rombola, Jacqueline Fernley and Stephane Chatonsky.
Termination	The SID may be terminated: (a) by either party for failure of conditions; (b) by mutual agreement; (c) if the Scheme has not become effective by the End Date (being the date 6 months from the date of execution of the SID); (d) by either party if a court or other Regulatory Authority issues a final and non-appealable order which permanently restrains or prohibits the Scheme; or (e) by either party if the Court refuses to convene the Scheme Meeting.

Material term	Description
Confidentiality	The parties remain bound by the Confidentiality Deed executed in March 2026, which survives termination of the SID.
Governing Law	The laws of New South Wales.

SCHEDULE 3: MATERIAL TERMS OF CONSIDERATION OPTIONS AND ADDITIONAL OPTIONS

CONSIDERATION OPTIONS

Under the Proposed Scheme, holders of Scheme Options will receive that number of new GSS Options calculated by multiplying every 1 Microba MAPAR option and every 1 Microba MAPAQ option held by the Scheme Formula (**Consideration Options**). Other than in respect of the exercise price, the Consideration Options will be on the same terms as each holder's Microba MAPAR Options and Microba MAPAQ Options.

A summary of the material terms and conditions of the Consideration Options proposed to be issued is set out below.

A. MAPAR: Options Expiring 29 July 2029, Exercise Price \$0.0625

The Microba MAPAR Options were issued under the placement and Share Purchase Plan, approved by Microba Shareholders at the Microba Extraordinary General Meeting dated 24 July 2026.

In consideration for the acquisition of the Microba MAPAR Options, the Company proposes to issue GSS Options to the holders of the Microba MAPAR Options (**MAPAR Optionholders**) on the terms set out below.

Term	Description
Entitlement	Each Option entitles the MAPAR Optionholder to subscribe for one fully paid ordinary share upon exercise of the Option.
Exercise Price	The price calculated as the exercise price of the MAPAR Options divided by the Scheme Formula.
Expiry Date	5:00pm (Sydney time) on the date that is 3 years following their issue (i.e. 29 July 2029). Any Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
Exercise Period	The Options are exercisable at any time and from time to time on or prior to the Expiry Date.
Quotation	The Company does not intend to apply for official quotation of the Options.
Transferability	The Options are freely transferable.
Notice of Exercise	The Options may be exercised by notice in writing to the Company in a form reasonably acceptable to the Company and payment of the Exercise Price for each Option being exercised in Australian currency by BPAY or electronic funds transfer. Any notice received by the Company will be deemed to be a notice of the exercise of that Option as at the date of receipt.
Shares Issued on Exercise	Shares issued on exercise of the Options will rank equally with the then issued shares of the Company.
Participation in New Issues	There are no participation rights or entitlements inherent in the Options and MAPAR Optionholders will not be entitled to participate in new issues of capital offered to shareholders during the currency of the Options.
Adjustment for Bonus Issues of Shares	If the Company makes a bonus issue of shares or other securities to existing shareholders (other than an issue in lieu of or in satisfaction of dividends or by way of dividend reinvestment): (a) the number of shares which must be issued on the exercise of an Option will be increased by the number of shares which the MAPAR Optionholder would have received if the MAPAR Optionholder had

Term	Description
	exercised the Option before the record date for the bonus issue; and (b) no change will be made to the Exercise Price.
Adjustment for Entitlements Issue	If the Company makes an issue of shares pro rata to existing shareholders (other than as a bonus issue to which the above will apply), there will be no adjustment of the Exercise Price of an Option or the number of shares over which the Options are exercisable.
Adjustments for Reorganisation	If there is any reorganisation of the issued share capital of the Company, the rights of the MAPAR Optionholders will be varied in accordance with the Listing Rules.

B. MAPAQ: Options Expiring 13 August 2027, Exercise Price \$0.14

The Microba MAPAQ Options were issued under the securities purchase plan (SPP) Offer and placement options offer, approved by Microba Shareholders at Microba's Extraordinary General Meeting dated 8 August 2025.

In consideration for the acquisition of the Microba MAPAQ Options, the Company proposes to issue GSS Options to the holders of Microba MAPAQ Options (**MAPAQ Optionholders**) on the terms set out below.

Term	Description
Entitlement	Each Option entitles the MAPAQ Optionholder to subscribe for one fully paid ordinary Share in the capital of the Company upon exercise of the Option.
Exercise Price	The price calculated as the exercise price of the MAPAQ Options divided by the Scheme Formula.
Expiry Date	5:00pm (Sydney time) on the date that is 24 months following their issue (i.e. 13 August 2027). Any Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
Exercise period	The Options are exercisable at any time and from time to time on or prior to the Expiry Date.
Quotation	The Company does not intend to apply for official quotation of the Options.
Transferability	The Options are freely transferable.
Notice of Exercise	The Options may be exercised by notice in writing to the Company in a form reasonably acceptable to the Company and payment of the Exercise Price for each Option being exercised in Australian currency by BPAY or electronic funds transfer. Any notice received by the Company will be deemed to be a notice of the exercise of that Option as at the date of receipt.
Shares Issued on Exercise	Shares issued on exercise of the Options will rank equally with the then issued shares of the Company.
Participation in New Issues	There are no participation rights or entitlements inherent in the Options and MAPAQ Optionholders will not be entitled to participate in new issues of capital offered to shareholders during the currency of the Options.
Adjustment for Bonus Issues of Shares	If the Company makes a bonus issue of shares or other securities to existing shareholders (other than an issue in lieu of or in satisfaction of dividends or by way of dividend reinvestment): (a) the number of shares which must be issued on

Term	Description
	the exercise of an Option will be increased by the number of shares which the MAPAQ Optionholder would have received if the MAPAQ Optionholder had exercised the Option before the record date for the bonus issue; and (b) no change will be made to the Exercise Price.
Adjustment for Entitlements Issue	If the Company makes an issue of shares pro rata to existing shareholders (other than as a bonus issue to which the above will apply), there will be no adjustment of the Exercise Price of an Option or the number of shares over which the Options are exercisable.
Adjustments for Reorganisation	If there is any reorganisation of the issued share capital of the Company, the rights of the MAPAQ Optionholders will be varied in accordance with the Listing Rules.

ADDITIONAL OPTIONS

In connection with the Proposed Scheme, the Company may issue holders of Non-Scheme Options, up to that number of new GSS Options calculated by multiplying every 1 Non-Scheme option held by the Scheme Formula (**Additional Options**). Other than in respect of the exercise price, the Additional Options will be on the same terms as each holder's Non-Scheme Options.

A summary of the material terms and conditions that each class of Additional Option proposed to be issued is set out below.

C. MAPAP: Sonic Option Expiring 13 January 2027, Exercise Price \$0.09

The option was issued by Microba to Sonic Healthcare Limited (**Sonic**), approved by Microba Shareholders at an Extraordinary General Meeting of Microba dated 8 August 2025 (**Sonic Option**).

In consideration for the acquisition of the Sonic Option, the Company proposes to issue an Additional Option to Sonic Healthcare Limited on the terms set out below.

Term	Description
Entitlement	The Sonic Option entitles Sonic to subscribe for a maximum of 21,995,746 Shares, and a maximum of 5,498,936 further options, being one further option (Sonic Attaching Option) for every four Shares issued on exercise of the Sonic Option. Each Sonic Attaching Option is exercisable into one Share.
Exercise Price	The price calculated as the exercise price of the MAPAP Options divided by the Scheme Formula.
Sonic Attaching Options	Each Sonic Attaching Option has an exercise price at a 20% premium to the Exercise Price of the Sonic Option and expires at 5:00pm (Sydney time) on the date that is 36 months following their issue. The Sonic Attaching Options are otherwise on the same terms as the Sonic Option.
Expiry Date	5:00pm (Sydney time) on the day that is 17 months following the date of issue of the Sonic Option (i.e. approximately 13 January 2027). The Sonic Option will automatically lapse on the Expiry Date.
Exercise Period	The Sonic Option is exercisable at any time and from time to time on or prior to the Expiry Date.
Quotation	The Company will not apply for official quotation of the Sonic Option.

Term	Description
Transferability	The Sonic Option is transferable to a Related Body Corporate (as defined in the Corporations Act) of Sonic and otherwise, as approved by the Board.
Exercise – Takeover Provisions	Any exercise by Sonic of the Sonic Option is subject to compliance with the takeover prohibitions of the Corporations Act (sections 606 and 611).
Notice of Exercise	The Sonic Option may be exercised by notice in writing to the Company in a form reasonably acceptable to the Company and payment of the Exercise Price in Australian currency via BPAY or electronic funds transfer. Any notice received by the Company will be deemed to be a notice of the exercise of that option as at the date of receipt.
Shares and Sonic Attaching Options Issued on Exercise	Shares issued on exercise of the Sonic Option will rank equally with the then issued shares of the Company. In addition, each exercised Sonic Option will entitle Sonic to one Sonic Attaching Option for every four Shares issued.
Participation in New Issues	There are no participation rights or entitlements inherent in the Sonic Option and Sonic will not be entitled to participate in new issues of capital offered to shareholders during the currency of the Sonic Option.
Adjustment for Bonus Issues of Shares	If the Company makes a bonus issue of shares or other securities to existing shareholders (other than an issue in lieu of or in satisfaction of dividends or by way of dividend reinvestment): (a) the number of shares which must be issued on the exercise of the Sonic Option will be increased by the number of shares which Sonic would have received if Sonic had exercised the Sonic Option before the record date for the bonus issue; and (b) no change will be made to the Exercise Price.
Adjustment for Entitlements Issue	If the Company makes an issue of shares pro rata to existing shareholders (other than as a bonus issue to which the above will apply), there will be no adjustment of the Exercise Price of the Sonic Option or the number of shares over which the Sonic Option is exercisable.
Adjustments for Reorganisation	If there is any reorganisation of the issued share capital of the Company, Sonic's rights will be varied in accordance with the Listing Rules.

D. MAPAN: Options Expiring 28 January 2027, Exercise Price \$0.2715

The MAPAN Options are Director Options issued under the Microba Employee Incentive Plan to Jacqueline Fernley (**MAPAN Optionholder**), approved by Microba Shareholders at Microba's Annual General Meeting dated 30 November 2023 (**MAPAN Options**).

In consideration for the acquisition of the MAPAN Options, the Company proposes to issue Additional Options to the MAPAN Optionholder on the terms set out below.

Term	Description
Number and Vesting	200,000 Options issued in three tranches: (a) 67,000 Options vesting 12 months after the date of issue; (b) 67,000 Options vesting 24 months after the date of issue; and (c) 66,000 Options vesting 36 months after the date of issue.

Term	Description
Exercise Price	The price calculated as the exercise price of the MAPAN Options divided by the Scheme Formula.
Exercise Period	From the relevant Vesting Date to the date that is 37 months following the date of issue (i.e. 28 January 2027).
Issue Price	Nil.
Quotation	The Company will not seek official quotation of the Options.
Rights attaching	Shares issued on exercise of the Options will rank equally with the then issued shares of the Company.
Transferability	The Options may not be transferred or assigned unless otherwise determined by the Board or required by law.
Cashless Exercise	The MAPAN Optionholder may elect to set off the Exercise Price against the number of shares to which they are entitled upon exercise (Cashless Exercise Facility), in which case the MAPAN Optionholder will only be issued the number of shares equal in value to the difference between the total Exercise Price otherwise payable and the then market value of the shares.
Lapse	The Options will automatically lapse and be cancelled for no consideration at the earliest of: (a) subject to the good leaver and bad leaver provisions, 10 business days after the cessation of employment, contractual engagement or office; (b) where fraudulent or dishonest actions have occurred or where the Board has determined that the MAPAN Optionholder has brought the group into disrepute or acted contrary to its interests; (c) if applicable performance criteria and/or vesting conditions are not achieved by the relevant time; (d) the Expiry Date; or (e) any other circumstances specified in the offer letter.
Adjustments	In the event of any variation in share capital (such as a consolidation, subdivision, reduction or capital return), the number of Options will be adjusted in accordance with the applicable ASX Listing Rules. If there is a pro-rata issue of new shares, the Exercise Price or number of underlying shares will be adjusted in accordance with the ASX Listing Rules. If the Company makes a bonus issue of shares to existing shareholders, the number of shares which must be issued on exercise will be increased to the number of shares which the MAPAN Optionholder would have received if the Options had been exercised before the record date for the bonus issue.
No Dividend, Voting or Participation Rights	The MAPAN Optionholder is not entitled to: (a) notice of, or to vote or attend at, a meeting of shareholders; (b) receive any dividends declared by the Company; (c) participate in any new issues of securities offered to shareholders during the term of the Options; or (d) cash for the Options or any right to participate in surplus assets or profits of the Company on winding up, unless and until the Options are exercised and the MAPAN Optionholder holds shares.
Change of Control	Where the Company announces a Change of Control Event has occurred or is likely to occur (being approval of a scheme of arrangement, a takeover bid, a person acquiring more than 50.1% of the issued shares, or the sale of the business): (a) the MAPAN Optionholders may exercise their Options regardless of the vesting conditions having been satisfied; and (b) where an offer has been made to the MAPAN Optionholders on like terms to the terms proposed in relation to issued shares under the Change of Control Event and that offer has not been accepted by

Term	Description
	the end of the offer period, the Options will lapse within 10 days of the end of that offer period.

E. MAPAJ: Options Expiring 28 July 2027, Exercise Price \$0.4532

The MAPAJ Options were issued under the Microba Employee Incentive Plan adopted by the Microba board on 27 September 2021.

In consideration for the acquisition of the MAPAJ Options, the Company proposes to issue Additional Options to the holders of MAPAJ Options (**MAPAJ Optionholders**) on the terms set out below.

Term	Description
Entitlement and Vesting	Each vested Option entitles the MAPAJ Optionholder to subscribe for one fully paid ordinary share in the capital of the Company on payment of the Exercise Price. Options will only vest and be exercisable if the applicable Performance Criteria and/or Vesting Conditions (if any) specified in the Offer have been satisfied, waived by the Board, or are deemed to have been satisfied under the Plan rules. In the event of a Liquidity Event, the Board may in its absolute discretion waive any vesting or exercise criteria.
Exercise Price	The price calculated as the exercise price of the MAPAJ Options divided by the Scheme Formula.
Exercise Period	The Exercise Period and Expiry Date will be as determined by the Board. The Options expire on 28 July 2027. If the MAPAJ Optionholder is prohibited from exercising vested Options under Applicable Law on or in the ten (10) business days before the Expiry Date, the Expiry Date is automatically extended to the date that is five (5) business days after the MAPAJ Optionholder is no longer prohibited from exercising the Option.
Issue Price	Nil
Quotation	The Company will not seek official quotation of the Options.
Transferability	The Options may not be assigned, transferred, encumbered with a Security Interest or otherwise disposed of by the MAPAJ Optionholder unless: (a) the prior consent of the Board is obtained; or (b) such assignment or transfer occurs by force of law upon the death or total and permanent disablement of an MAPAJ Optionholder to the MAPAJ Optionholder's legal personal representative.
Method of Exercise	The Options are exercisable by the MAPAJ Optionholder delivering to the Company: (a) a signed Notice of Exercise; and (b) payment of the Exercise Price. The MAPAJ Optionholder may elect to use the Cashless Exercise Facility, under which the MAPAJ Optionholder will only be issued a number of Shares (rounded down to the nearest whole number) equal in value to the difference between the total Exercise Price otherwise payable and the then market value of the Shares at the time of exercise, calculated using the formula: $S = O \times (MSP - EP) / MSP$, where S = number of Shares to be issued, O = number of Options being exercised, MSP = volume weighted average price of Shares on ASX for the 5 trading days immediately prior to (and excluding) the date of the Notice of Exercise, and EP = Exercise Price. If the difference is zero or negative, the Cashless Exercise Facility may not be used. Options must be exercised in multiples of 1,000 unless fewer than 1,000 are held or the Board otherwise agrees.

Term	Description
Shares Issued on Exercise	Following receipt of a valid Notice of Exercise and payment of the Exercise Price, the Company must allot and issue the Shares, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act (or, if unable, lodge with ASIC a prospectus prepared in accordance with the Corporations Act to satisfy section 708A(11)), and apply for official quotation on ASX of the Shares, within twenty (20) business days. Shares issued on exercise rank equally with all existing Shares.
Lapse	The Options will automatically lapse and be cancelled for no consideration at the earliest of: (a) subject to the good leaver and bad leaver provisions, 10 business days after the cessation of employment, contractual engagement or office; (b) where fraudulent or dishonest actions have occurred or where the Board has determined that the MAPAJ Optionholder has brought the group into disrepute or acted contrary to its interests; (c) if applicable Performance Criteria and/or Vesting Conditions are not achieved by the relevant time; (d) the Expiry Date; or (e) any other circumstances specified in the offer letter. Where a MAPAJ Optionholder is a Good Leaver, vested Options which have not been exercised will continue in force and remain exercisable for 90 days, after which they will lapse. Where a MAPAJ Optionholder is a Bad Leaver, all vested and unvested Options will lapse.
Adjustments	In the event of any variation in share capital (such as a consolidation, subdivision, reduction or capital return), the number of options will be adjusted in accordance with the applicable ASX Listing Rules so that the MAPAJ Optionholder does not suffer any material detriment. If the Company makes an issue of Shares pro rata to existing shareholders (other than a bonus issue), the Exercise Price of an option will be reduced according to the formula: $\text{New exercise price} = O - E(P - (S + D)) / (N + 1)$, where O = old Exercise Price, E = number of underlying Shares into which one option is exercisable, P = average market price per Share weighted by reference to volume for the 5 trading days ending the day before the ex rights date, S = subscription price per Share under the pro rata issue, D = dividend due but not yet paid on existing Shares, and N = number of Shares with rights that must be held to receive one new Share. If the Company makes a bonus issue of Shares to existing shareholders (other than in lieu of dividends or by way of dividend reinvestment): (a) the number of Shares which must be issued on exercise will be increased to the number the MAPAJ Optionholder would have received if the options had been exercised before the record date for the bonus issue; and (b) no change will be made to the Exercise Price.
No Dividend, Voting or Participation Rights	The MAPAJ Optionholder is not entitled to: (a) notice of, or to vote or attend at, a meeting of shareholders; (b) receive any dividends declared by the Company; (c) participate in any new issues of securities offered to shareholders during the term of the options; or (d) cash for the Options or any right to participate in surplus assets or profits of the Company on winding up, unless and until the Options are exercised and the MAPAJ Optionholder holds Shares.
Change of Control	Where the Company announces a Change of Control Event has occurred or is likely to occur (being approval of a scheme of arrangement, a takeover bid, a person acquiring more than 50.1% of the issued Shares, or the sale of the business): (a) the MAPAJ Optionholder may exercise their Options regardless of the Vesting Conditions having been satisfied; and (b) where an offer has been made to the holder on like terms to the terms proposed in relation to issued Shares under the Change of Control Event and that offer has not been accepted by the end of the offer period, the Options will lapse within 10 days of the end of that offer period.
Buy-Back	The Options are subject to the Company's right to buy-back and may be bought back by the Company for an aggregate of \$1.00 for all relevant Options if: (a) the

Term	Description
	MAPAJ Optionholder ceases employment or office where the Vesting Conditions have not been met; (b) the bad leaver provisions apply; (c) the fraudulent or dishonest actions provisions apply; or (d) the Options have lapsed.

F. MAPAK: Options Expiring 28 July 2027, Exercise Price \$0.6382

The MAPAK Options were issued under the Microba Employee Incentive Plan adopted by the Microba board on 27 September 2021.

In consideration for the acquisition of the MAPAK Options, the Company proposes to issue Additional Options to the holders of MAPAK Options (**MAPAK Optionholders**) on the terms set out below in addition to the terms of the MAPAJ options as set out in section E above.

Term	Description
Exercise Period	The Exercise Period and Expiry Date will be as determined by the Board. The Options expire on 28 July 2027. If the MAPAK Optionholder is prohibited from exercising vested Options under Applicable Law on or in the ten (10) business days before the Expiry Date, the Expiry Date is automatically extended to the date that is five (5) business days after the MAPAK Optionholder is no longer prohibited from exercising the Option.
Exercise Price	The price calculated as the exercise price of the MAPAK Options divided by the Scheme Formula.

G. MAPAO: Options Expiring 10 February 2029, Exercise Price \$0.379

The MAPAO Options were issued under the Microba Employee Incentive Plan adopted by the Microba board on 27 September 2021.

In consideration for the acquisition of the MAPAO Options, the Company proposes to issue Additional Options to the holders of MAPAO Options (**MAPAO Optionholders**) on the terms set out below in addition to the terms of the MAPAJ options as set out in section E above.

Term	Description
Exercise Period	The Exercise Period and Expiry Date will be as determined by the Board. The Options expire on 10 February 2029. If the MAPAO Optionholder is prohibited from exercising vested Options under Applicable Law on or in the ten (10) business days before the Expiry Date, the Expiry Date is automatically extended to the date that is five (5) business days after the MAPAO Optionholder is no longer prohibited from exercising the Option.
Exercise Price	The price calculated as the exercise price of the MAPAO Options divided by the Scheme Formula.

H. MAPAS: Options Expiring 29 July 2029, Exercise Price \$0.075

These Options were issued to the Joint Lead Managers (Morgans Corporate Limited and Canaccord Genuity (Australia) Limited) and Latimer Partners (**Broker Options**), approved by Microba Shareholders at the Microba Extraordinary General Meeting dated 24 July 2026.

In consideration for the acquisition of the Broker Options, the Company proposes to issue Additional Options to the holders of the Broker Options (**Broker Optionholders**) on the terms set out below.

Term	Description
Exercise Price	The price calculated as the exercise price of the MAPAS Options divided by the Scheme Formula.
Expiry Date	5:00pm (Sydney time) on the date that is 3 years following their issue. Any Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
Exercise Period	The Options are exercisable at any time and from time to time on or prior to the Expiry Date.
Quotation	The Company does not intend to apply for official quotation of the Options.
Transferability	The Options are transferable to a Related Body Corporate (as defined in the Corporations Act) of the Joint Lead Managers or Latimer Partners and otherwise as approved by the Board.
Notice of Exercise	The Options may be exercised by notice in writing to the Company in a form reasonably acceptable to the Company and payment of the Exercise Price for each Option being exercised in Australian currency by BPAY or electronic funds transfer. Any notice received by the Company will be deemed to be a notice of the exercise of that Option as at the date of receipt.
Shares Issued on Exercise	Shares issued on exercise of the Options will rank equally with the then issued shares of the Company.
Participation in New Issues	There are no participation rights or entitlements inherent in the Options and Broker Optionholders will not be entitled to participate in new issues of capital offered to shareholders during the currency of the Options.
Adjustment for Bonus Issues of Shares	If the Company makes a bonus issue of shares or other securities to existing shareholders (other than an issue in lieu of or in satisfaction of dividends or by way of dividend reinvestment): (a) the number of shares which must be issued on the exercise of an Option will be increased by the number of shares which the Broker Optionholders would have received if the Broker Optionholder had exercised the Option before the record date for the bonus issue; and (b) no change will be made to the Exercise Price.
Adjustment for Entitlements Issue	If the Company makes an issue of shares pro rata to existing shareholders (other than as a bonus issue to which the above will apply), there will be no adjustment of the Exercise Price of an Option or the number of shares over which the Options are exercisable.
Adjustments for Reorganisation	If there is any reorganisation of the issued share capital of the Company, the rights of the Broker Optionholders will be varied in accordance with the Listing Rules.

SCHEDULE 4: EFFECT OF PROPOSED SCHEME ON COMPANY

The table below includes the financial information of the Company from its most recent audited accounts for the full financial year ended 30 June 2026 and sets out the pro-forma information to account for the effect of the Proposed Scheme. The pro-forma information has been prepared on the basis set out in the notes below the table. The pro-forma information does not take into account the effect of the Microba Placement on the Company.

Key financial measure	Existing (\$)	Effect of Proposed Scheme			
		Pro-forma adjustment (\$)	Pro-forma merged group (\$)	% change	Scale of change
Total assets ²	38,457,000	40,769,722	79,226,722	106%	2.06
Total equity ²	35,723,000	25,341,688	61,064,688	71%	1.71
Net revenue from ordinary activities	14,840,000	14,758,461	29,598,461	99%	1.99
Annual expenditure ³	34,322,000	37,650,469	71,972,469	110%	2.10
EBITDA ⁴	(10,802,000)	(15,904,131)	(26,706,131)	147% ⁵	2.47
Profit / (loss) before tax ⁴	(14,006,000)	(20,983,968)	(34,989,968)	150% ⁵	2.50
Issued shares	227,138,828	340,708,242	567,847,070	150%	2.50
Issued options, performance rights and restricted rights	3,505,780	129,745,003	133,250,784	3701%	38.01

Notes:

- Basis of preparation:** The pro-forma information is based on the audited financial statements of GSS and Microba for the financial year ended 30 June 2026. The GSS statements were audited by BDO Audit Pty Ltd and the Microba statements by Pitcher Partners. Microba's audit report includes a material uncertainty related to going concern. The revenue, annual expenditure, EBITDA and profit before tax measures are presented as if the Proposed Scheme had been implemented on 1 July 2025. Total assets and total equity are presented as if it had been implemented on 30 June 2026. Two further items are reflected in total assets and total equity: the issue by Microba on 29 July 2026 of 16,809,785 shares at \$0.05 under its Tranche 2 placement and SPP, raising \$840,489; and estimated transaction costs of the Proposed Scheme of \$1,500,000, which are assumed to be paid in cash and expensed. The pro-forma information is illustrative only, and has not been audited or reviewed. It does not reflect trading by GSS or Microba after 30 June 2026, nor does it take into account the effect of the Microba Placement on the Company.
- Total assets and total equity:** The pro-forma adjustments to total assets and total equity reflect the accounting impact of the securities issued by GSS in connection with the Proposed Scheme, being the Relevant Securities, rather than an aggregation of the existing total equity of GSS and Microba. They have been calculated as follows:
 - GSS as accounting acquirer:** GSS has concluded, on a preliminary basis, that GSS is the acquirer for the purposes of AASB 3 *Business Combinations*. In reaching this conclusion, GSS has had regard to the following factors: GSS is the entity issuing the Relevant Securities and the combination is structured as an acquisition of Microba by GSS; the merged group will retain GSS's name, ASX listing and code; GSS contributes the larger share of the merged group's net assets (\$35.7 million compared with \$24.4 million) and cash and term deposits (\$22.1 million compared with \$7.9 million); no Microba shareholder is expected to obtain voting power of 20% or more, and Microba Shareholders are not expected to act as an organised group; and the board of the merged group will comprise three existing GSS directors and three Microba nominees. GSS acknowledges that Microba Shareholders will hold a majority (60%) of the GSS Shares on Implementation, which is an indicator to the contrary under AASB 3. Having weighed that indicator against the factors above, GSS has concluded that it is the acquirer. This conclusion remains subject to confirmation by GSS's auditor. Accordingly, GSS's assets and liabilities are carried forward at their historical carrying amounts. Microba's identifiable assets and liabilities are recognised at fair value, and Microba's pre-acquisition equity is eliminated on consolidation.
 - Consideration Shares:** The 340,708,242 Consideration Shares are measured at their fair value. This is based on GSS's closing share price of [\$0.074 on 22 September 2026], which gives [\$25,212,410]. This amount is recognised in issued capital. The final amount will be measured at GSS's share price on

Implementation. Each \$0.01 change in that price would change the value of the Consideration Shares, and therefore goodwill and total equity, by approximately [\$3.4 million].

- **Consideration Options and Additional Options:** The GSS Options issued to replace Microba Options form part of the purchase consideration. The Consideration Options have been valued at \$1,517,726 using a Black-Scholes model. The valuation assumes the terms set out in Schedule 3, including a number of GSS Options equal to the number of Microba Options multiplied by the Scheme Formula and an exercise price equal to the exercise price of the Microba Options divided by the Scheme Formula, a valuation date of 22 September 2026, together with a share price of \$0.074, volatility of 80% and a risk-free rate of 3.75%. The Additional Options, other than the Sonic option, have been valued on the same basis at [\$111,552]. This is the portion of their value attributable to service before Implementation; the MAPAS options, which were issued for services already provided, are included at their full fair value, and the employee options are included at their full fair value, most of them being significantly out-of-the-money. These amounts are recognised in reserves. The Sonic option is classified as a derivative financial liability and is therefore not equity consideration. It has been carried at Microba's carrying amount of [\$28,864].
- **Goodwill:** No purchase price allocation has yet been performed. Microba's carrying amounts have been assumed to approximate fair value, except that Microba's existing goodwill of \$9,198,124 has been eliminated. Provisional goodwill of \$10,818,323 arises, calculated as set out below. The final purchase price allocation is expected to identify intangible assets separately from goodwill, such as Microba's technology platform, Microbiome Discovery Database, customer and partner relationships and therapeutics intellectual property. Any such intangible assets with finite lives would give rise to additional amortisation expense, which is not reflected in the pro-forma EBITDA or profit before tax. Goodwill will be tested for impairment at least annually.

The components of the adjustment to total equity, and the calculation of provisional goodwill, are:

Pro-forma adjustment to total equity	\$
Consideration Shares – 340,708,242 GSS Shares at \$0.074 (recognised in issued capital)	[25,212,410]
Consideration Options – fair value (recognised in reserves)	[1,517,726]
Additional Options (excluding the Sonic option) – value attributable to pre-combination service (recognised in reserves)	[111,552]
Estimated transaction costs of the Proposed Scheme (expensed)	(1,500,000)
Pro-forma adjustment to total equity	25,341,688

Provisional goodwill on acquisition of Microba	\$
Purchase consideration (Consideration Shares, Consideration Options and Additional Options)	26,841,688
Less: Microba net assets at 30 June 2026	(24,381,000)
Less: Microba Tranche 2 placement and SPP completed 29 July 2026	(840,489)
Add back: Microba's existing goodwill (not an identifiable asset of the acquiree)	9,198,124
Provisional goodwill	10,818,323

3. **Annual expenditure:** Annual expenditure is the total expenses recognised in the statement of profit or loss. It includes cost of materials and freight or cost of sales, depreciation and amortisation, impairment and finance costs, and excludes income tax. For FY26, GSS's annual expenditure was \$34,322,000 and Microba's was \$37,650,469 (comprising cost of sales of \$7,732,289 and total operating expenses of \$29,918,180).
4. **EBITDA, profit before tax and expected synergies:** EBITDA is profit or loss before income tax, net finance costs, depreciation and amortisation and impairment expenses. It is a non-IFRS measure. GSS has considered whether the expected annualised gross cost synergies of \$2.5 million to \$3.0 million should be reflected in the pro-forma adjustments to EBITDA and profit before tax. It has concluded that they should not be reflected, for the following reasons:
 - The pro-forma information illustrates the effect of the Proposed Scheme on GSS's historical FY26 results. Pro-forma adjustments are limited to items that are directly attributable to the Proposed Scheme and factually supportable. The synergies were not achieved in FY26 and depend on integration actions that can only be taken after Implementation. Including them would convert historical information into

forward-looking financial information, which may only be disclosed where there are reasonable grounds for it (ASIC Regulatory Guide 170).

- The synergies are a preliminary, gross estimate. Their timing is uncertain, and they are stated before one-off costs to achieve them (such as redundancy and integration costs), which have not yet been quantified.
- GSS (approximately \$5 million per annum) and Microba (approximately \$7 million per annum) have each announced standalone cost reduction programs taking effect from FY27, which are also not reflected. Reflecting only the merger synergies, which may overlap with those programs, would present an inconsistent picture of the merged group's cost base.

For information only, and not as a pro-forma adjustment: had gross synergies of \$2.5 million to \$3.0 million been realised in full across FY26, before any costs to achieve them, pro-forma EBITDA would have been a loss of between \$24,206,131 and \$23,706,131. Pro-forma profit before tax would have been a loss of between \$32,489,968 and \$31,989,968. There is no certainty that the synergies will be achieved in the amounts or within the timeframe expected.

5. **% change for loss measures:** GSS, Microba and the merged group each incurred losses in FY26. For EBITDA and profit before tax, the % change represents the increase in the size of the loss.
6. **Issued shares and options:** The pro-forma figures for issued shares and options are estimates, as the precise number of Relevant Securities remains subject to finalisation. Issued shares are calculated using the Scheme Formula and depend on the number of GSS Shares on issue at the Scheme Record Date. Options are calculated by multiplying the number of Microba Options by the Scheme Formula (approximately 0.4751 GSS Options per Microba Option as at the Relevant Date), rounded down. They include the maximum number of Additional Options, including 5,498,936 in respect of the Sonic option. The Sonic option and the MAPAN options expire on or about 13 January 2027 and 28 January 2027 respectively, before the indicative Implementation date, and will lapse unless exercised before then. These adjustments are based on the number of Microba Shares and Microba Options on issue as at the Relevant Date, and are therefore subject to change.

SCHEDULE 5: INDICATIVE TIMETABLE OF SCHEME IMPLEMENTATION

Event	Indicative date
GSS AGM	16 November 2026
Execution of Scheme Implementation Deed (subject to receiving GSS Shareholder approval)	Late November 2026
Lodgement of Scheme Booklet with ASIC	Mid-to-late December 2026
First Court hearing	January 2027
Despatch of Scheme Booklet to Microba shareholders	January 2027
Microba Scheme Meeting	February 2027
Second Court hearing	February 2027
Scheme becomes effective	February / March 2027
Scheme record date	February / March 2027
Implementation date and issue of new GSS shares and options	March 2027 (and in any event no later than 16 May 2027)

Annexure A Microba FY 26 Annual Report

The Microba FY 26 Annual Report can be accessed via the following link:

[Link to Microba Annual Report FY26](#)

23 October 2026

**Addendum to the Annual General Meeting of Genetic Signatures Limited
to be held on Monday, 16 November 2026**

Dear Shareholder

Important Update – Addendum to Notice of Annual General Meeting

Since the Notice of Annual General Meeting was released on 16 October 2026 (**Notice of Meeting**), Genetic Signatures Limited (ASX:GSS) (**GSS** or the **Company**) has issued an addendum to the Notice of Meeting (**Addendum**), which includes an additional resolution to be considered by Shareholders at the Annual General Meeting (**AGM**).

Shareholders are encouraged to read the Addendum carefully in conjunction with the Notice of Meeting. Shareholders who have already submitted a Proxy Form should review the section titled “**Replacement Proxy Form**” in the Addendum to determine whether any action is required.

The **Addendum**, together with a **Replacement Proxy Form**, is available at:

<https://geneticsignatures.com/au/investors/announcements/>

To view the **Notice of Annual General Meeting** and the **Addendum**, please use the following link:

<https://geneticsignatures.com/au/investors/announcements/>

To view the **2026 Annual Report**, please use the following link:

<https://geneticsignatures.com/au/investors/reports/>

VOTING IS NOW OPEN. To vote online, please follow the instructions below:

- **STEP 1:** Visit <https://www.votingonline.com.au/gssagm2026>
- **STEP 2:** Enter your Postcode (if within Australia) OR Country of Residence (if outside Australia)
- **STEP 3:** Enter your Voting Access Code (VAC) – as contained in the attached Proxy Form
- **STEP 4:** Follow the prompts to vote on each resolution

Important Note: For your voting instructions to be valid and counted towards this AGM please ensure that your online lodgement is received no later than 9:00am (Sydney time) on Saturday, 14 November 2026. Voting instructions received after this time will not be valid for the scheduled AGM.

If you have any queries regarding your shareholding or the upcoming Genetic Signatures Limited AGM, please contact Boardroom Pty Limited on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia).

Yours faithfully



Sonya Tissera
Company Secretary
Genetic Signatures Limited